Confirms what we already know. No real surprises.
In this study, Cetuximab beat Bevacizumab in left sided KRAS wild type colon cancer.
Three trial updates confirm what we already know and practice.
Confirms what we already know. No real surprises.
Confirms what we already know. No real surprises.
Somewhat disappointing as this was a negative study, however it is still an option for patients who are not candidates for mFOLFIRINOX.
Although immunotherapy did not beat chemotherapy but was non inferior and with more favorable safety.
I welcome additional comments from our Radiology Oncologists, but it seems patients may not need axillary surgery, this eliminated adverse events such as lymphedema.
While use of Hydroxyurea for CMML may not be common practice, it is an option.
FCS medical oncologist and hematologist Lowell L. Hart, MD, FACP was first-author a study with FCS co-authors President and Managing Physician Lucio N. Gordan, MD, Director of Pharmacy Operations Kristen Boykin, Senior Vice President & Data Officer Trevor Heritage, PhD, and (Retired) Vice President of Pharmacy Services Ray Bailey BPharm, RPh, that evaluated ES-SCLC patients with chemotherapy-induced myelosuppression over a seven-year period, from January 2013 through December 2020. Within this cohort, 98% of the patients experienced at least one myelosuppressive episode following chemotherapy treatment, leading to the need for supportive care, creating additional costs in health care management and time lost in treatment for ES-SCLC.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
